Evidence map›Paper›PMID 32358674›Full record

ArticleInternational urology and nephrology2020

Screening for primary hyperparathyroidism in a tertiary stone clinic, a useful endeavor.

Carter J Boyd, Kyle D Wood, Nikhi Singh, Dustin Whitaker, Gerald McGwin, Herbert Chen, Dean G Assimos

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Carter J BoydUniversity of Alabama-Birmingham School of Medicine, Birmingham, AL, USA.
Kyle D WoodDepartment of Urology, University of Alabama-Birmingham, Faculty Office Tower 1107, 510 20th Street South, Birmingham, AL, 35249, USA.
Nikhi SinghUniversity of Alabama-Birmingham School of Medicine, Birmingham, AL, USA.
Dustin WhitakerUniversity of Alabama-Birmingham School of Medicine, Birmingham, AL, USA.
Gerald McGwinDepartment of Epidemiology, University of Alabama-Birmingham, Birmingham, AL, USA.
Herbert ChenDepartment of Surgery, University of Alabama-Birmingham, Birmingham, AL, USA.
Dean G AssimosDepartment of Urology, University of Alabama-Birmingham, Faculty Office Tower 1107, 510 20th Street South, Birmingham, AL, 35249, USA. deanassimos@uabmc.edu.
University of Alabama at Birmingham · US

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Sex hormones and arthritis in a long lived animal modelP30AG050886 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Jianhua Zhang · 2015 to 2026
$11.3M
UAB-UCSD O'Brien Center for Acute Kidney Injury ResearchU54DK137307 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PAUL W. SANDERS · 2023 to 2026
$4.4M
Obesity and Endogenous Oxalate SynthesisK08DK115833 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WOOD, KYLE D · 2018 to 2022
$960k
GLYCOLATE METABOLISM AND KIDNEY OXALATEK01DK114332 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FARGUE, SONIA · 2017 to 2021
$883k
NIA NIH HHS P30 AG050886NIDDK NIH HHS K01 DK114332NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626NIDDK NIH HHS U54 DK137307
6 · The paper itself

Abstract

INTRODUCTION AND

objectivesPrimary hyperparathyroidism (1HPT) is associated with the risk of developing kidney stones. Our objective was to determine the prevalence of 1HPT amongst SF evaluated at a tertiary stone clinic and determine if it is cost-effective to screen for this condition.

methodsWe retrospectively reviewed 742 adult SF seen by a single urologic surgeon from 2012 to 2017 all of who were screened for 1HPT with an intact serum PTH (iPTH) and calcium. The diagnosis of 1HPT was based on the presence of hypercalcemia with an inappropriately elevated iPTH or a high normal serum calcium and an inappropriately elevated iPTH. The diagnosis was confirmed by surgical neck exploration. Published cost data and stone recurrence rates were utilized to create a cost-effectiveness decision tree. RESULTS OBTAINED: Fifty-three (7.1%) were diagnosed with 1HPT. 15 (28%) had hypercalcemia and inappropriately elevated iPTH, 38 (72%) had high normal serum calcium levels and inappropriately elevated iPTH. The potential diagnosis was ignored/missed by primary care physicians in 9 (17.0%) based on a review of prior lab results. Cost modeling was undertaken for 5, 10, 15, and 20-year intervals after screening. Based on our prevalence data, historical risks for recurrence and published cost data for stone treatments, cost savings in screening are realized at 10 years.

conclusionThese results support screening for primary hyperparathyroidism in patients evaluated in a tertiary referral setting.

Indexed as

AdultAgedAged, 80 and overCost-Benefit AnalysisFemaleHumansHyperparathyroidism, PrimaryMaleMass ScreeningMiddle AgedRetrospective StudiesTertiary Care CentersCost analysisNephrolithiasisPrimary hyperparathyroidismScreening

Identifiers

PMID32358674
OpenAlexW3021815767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.